1/4: “This is supported by the National Institute for Health and Care Excellence’s guideline ‘Cannabis-based medicinal products’, which states that after the initial prescription, subsequent prescriptions of CBPMs may be issued by another prescriber ...
theyworkforyou.com/wrans/?id=2021…
theyworkforyou.com/wrans/?id=2021…
2/4: “as part of a shared care agreement under the direction of an initiating specialist prescriber, if:
- shared care is appropriate and in the person’s best interest;
- the person's clinical condition is stable; and” ...
- shared care is appropriate and in the person’s best interest;
- the person's clinical condition is stable; and” ...
3/4: - “the other prescriber is confident to make a fully informed prescribing decision about cannabis-based medicinal products.
If a GP accepts ongoing shared care responsibilities and continues prescribing once a patient has been initiated and stabilised on CBPMs,” ...
If a GP accepts ongoing shared care responsibilities and continues prescribing once a patient has been initiated and stabilised on CBPMs,” ...
4/4: “they must be confident to accept the associated legal and professional responsibilities associated with doing so, which are increased in the case of an unlicensed product. This includes accountability for the quality of the product prescribed” ...
5/ “Treatments initiated privately would not usually be prescribed by a GP under shared care unless the requested treatment is approved under existing NHS policies or there are exceptional circumstances.”
• • •
Missing some Tweet in this thread? You can try to
force a refresh
